Angelica Welch

Articles

Emerging Findings Offer Hope With Less Common Genomic Drivers of Lung Cancer

April 23rd 2018

Alexander Drilon, MD, discusses genomic drivers in non–small cell lung cancer as well as the current treatment options for patients who harbor those mutations.

Landgren Explains Evolving Myeloma Landscape

April 20th 2018

C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

Expert Highlights Evolving Role of BMT in Hematologic Malignancies

April 20th 2018

Koen van Besien, MD, PhD, shares his insights on challenges with bone marrow transplant and on the potential future for these technologies in a time when the landscape is undergoing many changes.

Therapeutic Options Continue to Grow for HCC

April 20th 2018

Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.

Triplets Reign Supreme in Relapsed/Refractory Myeloma

April 18th 2018

Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.

Shifting NSCLC Landscape Creates Confusion for PD-1/Chemo Combo

April 10th 2018

Ari VanderWalde, MD, explains his trepidation with combinations of chemotherapy and immunotherapy in NSCLC.

Surgical Challenges Remain Among Recent Successes in Kidney Cancer

April 10th 2018

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Expert Discusses Dramatic Larotrectinib Data in Pediatric Cancer

April 6th 2018

Ramamoorthy Nagasubramanian, MD, discusses the results of the phase I/II study of larotrectinib in pediatric patients.

PARP Inhibitors Continue to Impress in Ovarian Cancer

April 5th 2018

Michael Birrer, MD, PhD, discusses the effect that PARP inhibitors have had on the treatment of ovarian cancer, and the potential for combinations with these agents.

Novel Agents, CAR T Cells Reinvigorate ALL Landscape

April 5th 2018

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

AML Treatment Additions Encouraging, But MDS Landscape Still Facing Challenges

March 31st 2018

Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

Immunotherapy Arrives in Gastric Cancer

March 30th 2018

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Expert Sheds Light on Recent Advances in mCRC

March 29th 2018

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Expert Discusses Bone-Targeting Agents in Prostate Cancer

March 29th 2018

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Durvalumab Success Signifies New Era in Stage III NSCLC

March 28th 2018

Edward S. Kim, MD, recaps the findings from the PACIFIC study of durvalumab and discussed the treatment of patients with stage III NSCLC.

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

March 28th 2018

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Immunotherapy Combinations Emerging in NSCLC

March 24th 2018

Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.

Frontline Advances Continue in Castration-Sensitive Prostate Cancer

March 23rd 2018

James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.

Brufsky Discusses Biosimilar Breakthroughs and Challenges

March 21st 2018

Adam Brufsky, MD, PhD, comments the FDA approval of MYL-1401O and discusses the adoption of biosimilars in oncology.

Expert Shares Excitement Over Biosimilars in Oncology

March 20th 2018

Sunil Verma, MD, shares his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.